Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial
Abstract Four hundred myopic children randomly received atropine 0.02% (n = 138) or 0.01% (n = 142) in both eyes once-nightly or only wore single-vision spectacles (control group) (n = 120) for 2 years. Spherical equivalent refractive error (SER), axial length (AL), pupil diameter (PD), and amplitud...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-11-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-01708-2 |
| _version_ | 1818824874242605056 |
|---|---|
| author | Can Cui Xiujuan Li Yong Lyu Li Wei Bingxin Zhao Shiao Yu Junbo Rong Yanhui Bai Aicun Fu |
| author_facet | Can Cui Xiujuan Li Yong Lyu Li Wei Bingxin Zhao Shiao Yu Junbo Rong Yanhui Bai Aicun Fu |
| author_sort | Can Cui |
| collection | DOAJ |
| description | Abstract Four hundred myopic children randomly received atropine 0.02% (n = 138) or 0.01% (n = 142) in both eyes once-nightly or only wore single-vision spectacles (control group) (n = 120) for 2 years. Spherical equivalent refractive error (SER), axial length (AL), pupil diameter (PD), and amplitude of accommodation (AMP) were measured every 4 months. After 2 years, the SER changes were − 0.80 (0.52) D, − 0.93 (0.59) D and − 1.33 (0.72) D and the AL changes were 0.62 (0.29) mm, 0.72 (0.31) mm and 0.88 (0.35) mm in the 0.02% and 0.01% atropine groups and control group, respectively. There were significant differences between changes in SER and AL in the three groups (all P < 0.001). The changes in SER and AL in the 2nd year were similar to the changes in the 1st year in the three groups (all P > 0.05). From baseline to 2 years, the overall decrease in AMP and increase in PD were not significantly different in the two atropine groups, whereas the AMP and PD in the control group remained stable (all P > 0.05). 0.02% atropine had a better effect on myopia control than 0.01% atropine, and its effects on PD and AMP were similar to 0.01% atropine. 0.02% or 0.01% atropine controlled myopia progression and AL elongation synchronously and had similar effects on myopia control each year. |
| first_indexed | 2024-12-19T00:02:48Z |
| format | Article |
| id | doaj.art-5c697c8dcc7f4aa0a582daf78025bded |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-19T00:02:48Z |
| publishDate | 2021-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-5c697c8dcc7f4aa0a582daf78025bded2022-12-21T20:46:24ZengNature PortfolioScientific Reports2045-23222021-11-011111810.1038/s41598-021-01708-2Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trialCan Cui0Xiujuan Li1Yong Lyu2Li Wei3Bingxin Zhao4Shiao Yu5Junbo Rong6Yanhui Bai7Aicun Fu8The First Affiliated Hospital of Zhengzhou UniversityThe First Affiliated Hospital of Zhengzhou UniversityThe First Affiliated Hospital of Zhengzhou UniversityThe First Affiliated Hospital of Zhengzhou UniversityThe First Affiliated Hospital of Zhengzhou UniversityThe First Affiliated Hospital of Zhengzhou UniversityThe First Affiliated Hospital of Zhengzhou UniversityThe First Affiliated Hospital of Zhengzhou UniversityThe First Affiliated Hospital of Zhengzhou UniversityAbstract Four hundred myopic children randomly received atropine 0.02% (n = 138) or 0.01% (n = 142) in both eyes once-nightly or only wore single-vision spectacles (control group) (n = 120) for 2 years. Spherical equivalent refractive error (SER), axial length (AL), pupil diameter (PD), and amplitude of accommodation (AMP) were measured every 4 months. After 2 years, the SER changes were − 0.80 (0.52) D, − 0.93 (0.59) D and − 1.33 (0.72) D and the AL changes were 0.62 (0.29) mm, 0.72 (0.31) mm and 0.88 (0.35) mm in the 0.02% and 0.01% atropine groups and control group, respectively. There were significant differences between changes in SER and AL in the three groups (all P < 0.001). The changes in SER and AL in the 2nd year were similar to the changes in the 1st year in the three groups (all P > 0.05). From baseline to 2 years, the overall decrease in AMP and increase in PD were not significantly different in the two atropine groups, whereas the AMP and PD in the control group remained stable (all P > 0.05). 0.02% atropine had a better effect on myopia control than 0.01% atropine, and its effects on PD and AMP were similar to 0.01% atropine. 0.02% or 0.01% atropine controlled myopia progression and AL elongation synchronously and had similar effects on myopia control each year.https://doi.org/10.1038/s41598-021-01708-2 |
| spellingShingle | Can Cui Xiujuan Li Yong Lyu Li Wei Bingxin Zhao Shiao Yu Junbo Rong Yanhui Bai Aicun Fu Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial Scientific Reports |
| title | Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial |
| title_full | Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial |
| title_fullStr | Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial |
| title_full_unstemmed | Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial |
| title_short | Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial |
| title_sort | safety and efficacy of 0 02 and 0 01 atropine on controlling myopia progression a 2 year clinical trial |
| url | https://doi.org/10.1038/s41598-021-01708-2 |
| work_keys_str_mv | AT cancui safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT xiujuanli safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT yonglyu safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT liwei safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT bingxinzhao safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT shiaoyu safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT junborong safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT yanhuibai safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT aicunfu safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial |